Sigachi Industries-Undervalued
Business model
Sigachi operates predominantly across three segments:
Excipients (Microcrystalline Cellulose / MCC): core business; used as binder/disintegrant in pharma formulations; also used across multiple end markets.Sold under prominent brand names like HiCel and AceCel.[75-80%revenue]
O&M (Operations & Management services): Asset light- operates other companies factories , company earns based on outpout of the factory. steady contributor; clients includes birla, adani solar etc,[10-12% revenue]
API initiatives: acquisition of an 80% majority stake in Trimax Bio Sciences Private Limited. building API, R&D + regulated market readiness; CEP filing work [10% revenue]
Competitive Moats & Operational Strengths
Global Scale in MCC: Sigachi operates with an aggregate MCC production capacity approaching 30,000 MTPA(targeted fpr Q427, current 18000MTPA,) making it the largest manufacturer in India and a top-tier supplier globally.
Stringent Regulatory Accreditations: Facilities hold approvals from major global bodies (including US FDA, EDQM, EXCiPACT, ISO, Halal, and Kosher), creating high switching costs for pharmaceutical clients who cannot easily alter their approved drug formulations.
Global Exports: exports contribute 60% revenue , exports to 60+ countries
Growth Drivers & Capex Blueprint
1. Capacity Expansion in Core Excipients
Dahej SEZ Expansion: Sigachi has deployed capital to expand its Dahej manufacturing facility, adding new production lines to capture growing export demand in regulated Western markets.
In-house R&D: Development of specialized grades of MCC (high-density, low-moisture, co-processed excipients) that command higher realizations than standard powder grades.
2. Forward Integration into APIs
To reduce dependence on single-product cycles, Sigachi is expanding into API manufacturing through trimax bio acquistion(80%) leveraging its existing global B2B distribution network.(expanding from 100 KL to 250 KL) and ongoing filings for European CEP certifications.
3. Shift Toward High-Margin Specialty-CCS
Increasing the revenue share of specialty blends (CCS) which has better margins (20%+)
Key Investment Risks & Challenges
Raw Material Price Volatility: Primary raw materials—wood pulp and specialty cotton linter—are tied to global commodity prices and import freight rates. Spike in pulp costs directly squeezes gross margins.
Product Concentration: Despite diversification attempts, a significant majority of total revenues still originate from MCC and cellulose derivatives. (80%)
Execution Risk on API Pivot: Transitioning from an excipient vendor to an API and custom synthesis manufacturer involves distinct regulatory, technological, and marketing hurdles.
The revenue decline and loss from the last year is an one time off due to fire accident hsppened in hyderabad plant. Where whole plant got destroyed and 40 people died.which caused one time spending of 100+ crores and management said around 60crs revenue due to loss of hyd capacity.
The company is yet to receive insurance amount which is a good sign
Management expects 650 -670 crs revenue in 2027 with margin around 18% .
Please give your view on sigachi, would love to hear your opinions
Hi pls add your opinions in comments. Wanted to know your views